APOGEE THERAPEUTICS INC (APGE) Stock Overview
NASDAQ:APGE - US03770N1019 - Common Stock
APGE Key Statistics, Chart & Performance
The current stock price of APGE is 36.37 USD. In the past month the price decreased by -3.66%. In the past year, price decreased by -28.92%.
APGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About APGE
Company Profile
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Company Info
APOGEE THERAPEUTICS INC
221 Crescent St., Building 17, Suite 102B
Waltham MASSACHUSETTS US
Employees: 196
Phone: 16503945230
APOGEE THERAPEUTICS INC / APGE FAQ
What is the stock price of APOGEE THERAPEUTICS INC today?
The current stock price of APGE is 36.37 USD. The price decreased by -0.68% in the last trading session.
What is the ticker symbol for APOGEE THERAPEUTICS INC stock?
The exchange symbol of APOGEE THERAPEUTICS INC is APGE and it is listed on the Nasdaq exchange.
On which exchange is APGE stock listed?
APGE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APOGEE THERAPEUTICS INC stock?
15 analysts have analysed APGE and the average price target is 98.69 USD. This implies a price increase of 171.34% is expected in the next year compared to the current price of 36.37. Check the APOGEE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APOGEE THERAPEUTICS INC worth?
APOGEE THERAPEUTICS INC (APGE) has a market capitalization of 2.17B USD. This makes APGE a Mid Cap stock.
How many employees does APOGEE THERAPEUTICS INC have?
APOGEE THERAPEUTICS INC (APGE) currently has 196 employees.
What are the support and resistance levels for APOGEE THERAPEUTICS INC (APGE) stock?
APOGEE THERAPEUTICS INC (APGE) has a support level at 36.29 and a resistance level at 36.85. Check the full technical report for a detailed analysis of APGE support and resistance levels.
Should I buy APOGEE THERAPEUTICS INC (APGE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APGE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APGE, evaluating the profitability, health, valuation and growth aspects
- APOGEE THERAPEUTICS INC (APGE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APOGEE THERAPEUTICS INC (APGE) Sales and EPS estimates to see what analysts future expectations are.
- APOGEE THERAPEUTICS INC (APGE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APOGEE THERAPEUTICS INC (APGE) Insider and Institutional Ownership to learn about the owners and their transactions.
- APOGEE THERAPEUTICS INC (APGE) Stock Chart to make your own analysis
- APOGEE THERAPEUTICS INC (APGE) Latest news and press-releases to stay up to date.
Does APOGEE THERAPEUTICS INC (APGE) stock pay dividends?
APGE does not pay a dividend.
When does APOGEE THERAPEUTICS INC (APGE) report earnings?
APOGEE THERAPEUTICS INC (APGE) will report earnings on 2025-11-10, before the market open.
What is the Price/Earnings (PE) ratio of APOGEE THERAPEUTICS INC (APGE)?
APOGEE THERAPEUTICS INC (APGE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.13).
What is the Short Interest ratio of APOGEE THERAPEUTICS INC (APGE) stock?
The outstanding short interest for APOGEE THERAPEUTICS INC (APGE) is 20.27% of its float. Check the ownership tab for more information on the APGE short interest.
APGE Technical Analysis
APGE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APGE. While APGE has a great health rating, there are worries on its profitability.
APGE Financial Highlights
Over the last trailing twelve months APGE reported a non-GAAP Earnings per Share(EPS) of -4.13. The EPS decreased by -99.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.13% | ||
| ROE | -38.37% | ||
| Debt/Equity | 0 |
APGE Forecast & Estimates
15 analysts have analysed APGE and the average price target is 98.69 USD. This implies a price increase of 171.34% is expected in the next year compared to the current price of 36.37.